Corcept Therapeutics (CORT) Q3 2026 earnings review
Corcept cancer sales nearly double, but patient additions slow
Corcept Therapeutics, a maker of cortisol-modulating medications for hormone disorders and cancer, expanded both of its commercial franchises while profit multiplied. Third-quarter revenue rose 64% to $340 million as Lifyorli ovarian cancer sales nearly doubled from last quarter and older Cushing's syndrome medications grew 20%. Chief executive Joseph Belanoff kept the full-year plan unchanged, which by our math requires fourth-quarter revenue to climb another 14% to reach the middle of the range.
| Revenue | $340.5M +64% from a year ago |
|---|---|
| Lifyorli ovarian cancer sales | $91.4M +92% from last quarter |
| Korlym and generic sales | $249.1M +20% from a year ago |
| Full-year revenue outlook | Unchanged $1.1–1.2B (51% growth at middle) |
⚖️ Verdict: 🟢 Bullish
The story got better because the third quarter proved Corcept can hit the bottom of its annual revenue plan without needing a fourth-quarter jump. Strong sales in both franchises also lifted operating profit above a third of revenue. One caution: by our math new Lifyorli patient additions slowed to about 1,000 from 1,300 last quarter, and the liver disease drug now needs another mid-stage trial.
The question now is whether Lifyorli patients stay on therapy long enough to drive repeat revenue and whether the FDA approves relacorilant for Cushing's syndrome. Bulls see two compounding commercial drugs; bears see an undisclosed active patient count and a binary regulatory decision on a resubmitted application. The December 17 FDA decision and fourth-quarter Lifyorli sales will settle both debates.
🐂 Bull Case
Lifyorli Revenue Nearly Doubled in Its Second Quarter
Lifyorli, Corcept's new medication for platinum-resistant ovarian cancer, is building a second commercial business alongside its older hormone franchise. Chief executive Joseph Belanoff said "Lifyorli’s uptake in ovarian cancer has been both very rapid and broad" since its April launch. Third-quarter sales of the drug reached $91.4 million, up 92.2% from $47.6 million in the second quarter. More than 2,300 patients have now received the drug from over 1,700 doctors.
That performance matters because Lifyorli already brings in 26.8% of total revenue by our math, up from 18.6% last quarter. It reduces the drug maker's reliance on its older Cushing's syndrome product and shows that oncologists are prescribing the pill beyond the initial wave of early adopters.
What to watch: fourth-quarter Lifyorli sales and European Commission approval before year-end. Another sequential rise in sales would show that existing patients are staying on the medication long enough to compound the revenue base.
Cushing's Drug Sales Reached a Five-Quarter High
Corcept's older business sells Korlym and its authorized generic to treat Cushing's syndrome, a disorder caused by excess cortisol hormone. Belanoff said rising awareness of the condition is driving the endocrinology business. In October, American and European diabetes groups published a report that "recommends screening for hypercortisolism in diabetic patients with poor glucose control despite ongoing medications" and cites Korlym's active ingredient as a potential treatment.
Revenue from Korlym and its generic rose 20.0% from a year ago and 19.4% from last quarter to $249.1 million. That marks a second straight quarter of sequential growth after pharmacy vendor bottlenecks held growth below 8% in the first half of the year, putting the franchise back near the 21% annual pace needed for management's long-term targets.
What to watch: the Food and Drug Administration decision on relacorilant, a successor Cushing's drug, due by December 17, 2026. Approval would let Corcept shift patients to a proprietary pill before generic rivals erode Korlym further.
Slower Cost Growth Lifted Operating Margin Above 33%
Corcept spent heavily over the past year to hire oncology sales reps and prepare for product launches, which pushed the company into an operating loss in the first quarter. In the third quarter, revenue grew much faster than overhead, so profitability rebounded.
- Operating margin: 33.7% of revenue, up 28.8 percentage points from 4.9% a year ago by our math
- Research and development (clinical trial costs): 16.7% of revenue, down 16.5 percentage points from a year ago
- Selling, general and administrative (sales and overhead): 48.3% of revenue, down 11.4 percentage points from a year ago
What to watch: fourth-quarter operating expenses as new cancer and liver trials start. Keeping sales and overhead costs below half of revenue would confirm that the commercial team can handle higher prescription volume without another hiring wave.
Ovarian Cancer Trial Opened Earlier Treatment Lines
Corcept wants to expand Lifyorli into larger cancer groups by combining it with standard therapies. In the Phase 2 BELLA Part A trial for platinum-resistant ovarian cancer, adding the drug to chemotherapy and bevacizumab "demonstrated clinically meaningful median PFS of 7.2 months, ORR of 59 percent and OS of 88 percent at 6-months". Meanwhile, European regulators recommended approving Lifyorli in ovarian cancer before year-end.
Patients who had not taken bevacizumab before saw even stronger results, with 8.1 months before their cancer worsened and a 66% response rate. Because those patients were earlier in their treatment course, the data supports moving Lifyorli into front-line settings where patients stay on therapy longer.
What to watch: Phase 2 BELLA Part B and Part C readouts in platinum-sensitive ovarian and endometrial cancers by the end of 2027. Positive results would open patient pools much larger than platinum-resistant ovarian cancer.
🐻 Bear Case
Lifyorli Patient Additions Slowed as Active Count Stayed Hidden
Belanoff described Lifyorli's launch uptake as rapid, pointing to cumulative totals of more than 2,300 patients and 1,700 prescribing physicians since April 1. Those cumulative headlines mask how many patients actually started the drug during the third quarter and how many remain on treatment today.
By our math, subtracting last quarter's cumulative figures of 1,300 patients and 1,000 prescribers shows Corcept added about 1,000 new patients and 700 new doctors in the third quarter, down from the initial launch quarter's pace. The release again gave only cumulative starts rather than the number of active patients still taking the drug. If early patients stop treatment quickly, revenue growth will flatten once the initial backlog of waiting patients is treated.
What to watch: active on-therapy patient counts or treatment duration disclosures on the conference call and in the quarterly filing. Continued refusal to state how many patients remain on the drug would suggest shorter treatment duration than the clinical trial benchmark.
Full-Year Plan Still Needs a Fourth-Quarter Step-Up
Corcept kept its full-year revenue outlook at $1.1 billion to $1.2 billion after reporting $761.5 million across the first nine months of 2026. Last year, the company cut its annual revenue plan twice and still missed the lowered bottom end by 5%.
By our math, hitting the $1.15 billion middle of this year's range requires $388.5 million of fourth-quarter revenue, which is a 14.1% jump from the third quarter and 92.2% growth from a year ago. Third-quarter sales of $340.5 million barely cleared the $339.5 million bottom of the quarterly run rate implied by the second-half plan, leaving all the remaining climb for the final three months.
What to watch: fourth-quarter revenue against the $338.5 million needed to reach the $1.1 billion low end of the full-year plan. Falling short of $338.5 million would mark a second consecutive year of missing annual targets.
Liver Disease and ALS Timelines Pushed Further Out
Beyond hormones and cancer, Corcept is testing miricorilant for metabolic liver disease (MASH) and dazucorilant for amyotrophic lateral sclerosis (ALS), a fatal nerve disease. Chief development officer Bill Guyer said of the Phase 2b MONARCH liver study: "We plan to study higher doses, to see if miricorilant’s fat- and fibrosis-reducing activity can be realized without sacrificing its excellent tolerability."
In MONARCH Cohort A, 48 weeks of treatment improved liver scarring in 19% of biopsied patients, and Corcept will now run another Phase 2 trial at 100 mg daily instead of moving to Phase 3. Meanwhile, the Phase 3 ALS trial is listed as "Planned to begin next year" after originally being targeted for mid-2026. Both moves delay when these pipeline drugs could reach patients.
What to watch: formal first-patient dosing in the Phase 3 ALS trial in early 2027. Another delay past the first quarter would raise doubts about the regulatory path for the ALS program.
Risks this quarter didn't answer
Five standing business risks received no new numbers or updates in the third-quarter earnings release.
- Relacorilant FDA review in Cushing's syndrome: the December 17, 2026 decision date stands, with no update on whether the agency raised questions about the re-analyzed trial data.
- Teva generic Korlym litigation: unmentioned in the release; the quarterly filing's legal note will show if a competing generic launch is closer.
- Authorized generic share of Korlym volume: not disclosed in the release after sitting near 78% earlier this year; the filing's revenue note will break out price versus volume.
- Specialty pharmacy capacity: no update on whether Corcept added another pharmacy vendor for Q4 as planned.
- Cancer competition and Medicare rebates: no breakdown of how competing immunotherapy combinations or federal rebate rules affected net pricing.
💲 Other KPIs
Uncollected bills from customers — trade receivables — jumped 44.4% from last quarter and 85.8% since the end of 2025, by our math. That rose faster than the 32.9% quarterly increase in revenue, tying up working capital as the Lifyorli hospital and specialty distribution network expanded.
The diluted share count climbed 3.2% from a year ago and 4.1% from last quarter, by our math. The pharmaceutical company resumed stock buybacks with $43.7 million spent in the third quarter after buying nothing in the first half, but employee option exercises and stock grants added more shares than buybacks retired.
Cash and marketable securities rose by $117.7 million in the third quarter, up from a $29.2 million increase in the second quarter. Corcept generated enough cash from its $126.8 million quarterly profit and option exercises to fund $43.7 million of share repurchases while still building its cash reserve.
🔮 Guidance
Unchanged. The plan calls for about 51% full-year revenue growth at the $1.15 billion middle of the range. By our math, that leaves $388.5 million for the fourth quarter, up 92.2% from a year ago and 14.1% from the third quarter. It follows two raises earlier this year (+$50M in Q1, +$150M in Q2), and hitting the low end requires $338.5 million in Q4, just below Q3's $340.5 million.
❓ Key Questions
How many patients remain actively on Lifyorli treatment today?
Corcept reported over 2,300 cumulative patient starts since April, implying about 1,000 starts in Q3 versus 1,300 in Q2. Knowing how many patients are still taking the drug is the only way to separate repeat refills from one-time initial prescriptions.
What is the fourth-quarter outlook split between Korlym and Lifyorli?
Hitting the $1.15 billion middle of the full-year plan requires $388.5 million in Q4, up $48 million from Q3. Investors need to know whether management expects that jump to come from ovarian cancer or Cushing's syndrome.
Why does miricorilant need another Phase 2 MASH trial?
After the 48-week Phase 2b MONARCH readout, Corcept plans another Phase 2 study testing 100 mg daily rather than advancing to Phase 3. Management did not say whether the 19% fibrosis improvement fell short of internal bars for a pivotal trial.
Has the FDA asked for more information on relacorilant?
With the December 17, 2026 FDA decision date in Cushing's syndrome six weeks away, the release gave no update on review interactions. That decision determines whether Corcept can protect its hormone franchise from generic Korlym.